跳至主要内容
临床试验/EUCTR2005-001371-35-GB
EUCTR2005-001371-35-GB进行中(未招募)1 期

A Double-Blind, Placebo Controlled, Half-Head Design, CPO Solution Dose Ranging-Finding Study in Patients with Seborrhoeic Dermatitis of the Scalp - Dose Range-Finding Study

Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel Laboratories International Division)0 个研究点目标入组 60 人开始时间: 2005年4月20日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Provided written Informed Consent
  • 2. Male or female
  • 3. Aged 16 years and above
  • 4. Confirmed as having seborrhoeic dermatitis of the scalp
  • 5. Willing to have their hair washed only 3 or 4 times weekly for the four week treatment phase of the study, and always at the study site
  • 6. Overall scaling/flaking meets a minimum visual scaling score of 5, and differing between the bilateral study sites by a score of no more than 1
  • 7. Willing to have a small section of hair clipped in order to assist in the removal of scales for yeast sampling
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Patients with acute, weeping or infected scalp dermatoses
  • 2. Patients with a history of known or suspected intolerance to any of the ingredients of the investigaional product
  • 3. Patients who have received any unlicensed drug within the last 30 days or who are scheduled to receive an investigative drug other than the study medication during the period of the study
  • 4. Patients with systemic diseases which, in the opinion of the Investigator, may adversely influence their participation in the trial
  • 5. Female patients who are pregnant or lactating
  • 6. Patients considered unable or unlikely to attend the necessary follow-up visits
  • 7. Patients who have used oral steriods, or topical steriods on the scalp, within the previous 4 weeks
  • 8. Patients who have used any medicinal product (i.e. other than a cosmetic/toiletry anti-dandruff shampoo) for their scalp condition within the previous 4 weeks
  • 9. Employee of Sequani Clinical of Stiefel Laboratories, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee.

研究者

发起方
Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel Laboratories International Division)

相似试验

进行中(未招募)
1 期
A study to investigate whether Epeleuton capsules are effective as a treatment for high levels of triglycerides in the blood and type 2 diabetes, whether this medicine is safe and what is the best dose.
EUCTR2020-000065-16-LVAfimmune240
进行中(未招募)
1 期
A Study to Evaluate Safety and Efficacy of MBS2320 in Patients receiving therapy with Mehtotrexate (MTX) with moderate to severe Rheumatoid Arthritis, who have had an inadequate response to MTX aloneModerate to Severe Active Rheumatoid Arthritis (RA)MedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2020-005496-13-PLModern Biosciences Ltd.224
进行中(未招募)
不适用
A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1b Infection with Compensated Liver Disease
EUCTR2010-018361-33-HUArrow Therapeutics Ltd. (a member of the AstraZeneca group of companies)64
进行中(未招募)
1 期
A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1b Infection with Compensated Liver DiseaseChronic hepatitis C virus (genotype 1b) infectionMedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CMedDRA version: 12.1Level: LLTClassification code 10019744Term: Hepatitis CMedDRA version: 12.1Level: LLTClassification code 10019751Term: Hepatitis C virusMedDRA version: 12.1Level: LLTClassification code 10047457Term: Viral hepatitis C
EUCTR2010-018361-33-SKArrow Therapeutics Ltd. (a member of the AstraZeneca group of companies)64
进行中(未招募)
1 期
A study to investigate whether Epeleuton capsules are effective as a treatment for high levels of triglycerides in the blood and type 2 diabetes, whether this medicine is safe and what is the best dose.Hypertriglyceridemia and Type 2 DiabetesMedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2020-000065-16-DEAfimmune Ltd.240